FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2892005654> ?p ?o ?g. }

• W2892005654 endingPage "48" @default.
• W2892005654 startingPage "37" @default.
• W2892005654 abstract "This study seeks to define factors affecting the development of adverse reactions to intensive therapy of toxoplasmic retinochoroiditis with antifolate agents (pyrimethamine/sulfadoxine) and antibiotics followed by secondary antifolate prophylaxis. The study was of retrospective and observational nature. Medical files were reviewed of 551 patients suffering from ocular toxoplasmosis during 1994–2013. All patients were treated with the same protocol: 3-week intensive pyrimethamine/sulfadoxine plus antibiotic/steroid therapy. Three hundred and fourteen out of the 551 patients qualified for the subsequent 6-month long secondary antifolate prophylaxis. The type and occurrence rate of adverse reactions were taken into account. The probability of an adverse reaction during the intensive therapy phase was 33.4%. Hypertransaminasemia was the most common event observed in 24.6% of the patients, but it assumed a severe character in just 0.9%, with male gender and age over 25 years being the predisposing factors. Less common adverse effects included thrombocytopenia (8.3%), hypersensitivity skin reactions (3.0%), and abdominal pain (1.4%). The adverse effects of secondary antifolate prophylaxis, most commonly hypersensitivity skin reactions and hypertransaminasemia, followed by thrombocytopenia and abdominal pain, were observed in 4.9% of the patients. Ten of them (2.7%) had to discontinue the treatment while eight others continued with pyrimethamine alone without further adverse effects, which suggests that discontinuation of the sulfonamide decreased the propensity for adverse reactions. The treatment strategy in these patients differed from previous reports in that it used lower doses of pyrimethamine/sulfonamide, with no folinic acid supplementation. Nonetheless, the rate and severity of adverse events were no greater than those noticed with traditional regimens, with higher antifolate doses and folinic acid supplementation. We conclude that the dose and drug-mitigated treatment strategy we employed deserves consideration as a promising alternative to traditional treatments for ocular toxoplasmosis." @default.
• W2892005654 created "2018-09-27" @default.
• W2892005654 creator A5031472089 @default.
• W2892005654 creator A5031555208 @default.
• W2892005654 creator A5059191670 @default.
• W2892005654 creator A5069360360 @default.
• W2892005654 creator A5075756419 @default.
• W2892005654 date "2018-01-01" @default.
• W2892005654 modified "2023-09-23" @default.
• W2892005654 title "Adverse Reactions in Antifolate-Treated Toxoplasmic Retinochoroiditis" @default.
• W2892005654 cites W1599666894 @default.
• W2892005654 cites W1922615383 @default.
• W2892005654 cites W1935941048 @default.
• W2892005654 cites W1965481778 @default.
• W2892005654 cites W1991866410 @default.
• W2892005654 cites W1998375854 @default.
• W2892005654 cites W2012410709 @default.
• W2892005654 cites W2025598475 @default.
• W2892005654 cites W2033103553 @default.
• W2892005654 cites W2042090538 @default.
• W2892005654 cites W2068753700 @default.
• W2892005654 cites W2097452962 @default.
• W2892005654 cites W2098922030 @default.
• W2892005654 cites W2102976549 @default.
• W2892005654 cites W2106114797 @default.
• W2892005654 cites W2125048345 @default.
• W2892005654 cites W2125913333 @default.
• W2892005654 cites W2230428332 @default.
• W2892005654 cites W2254718306 @default.
• W2892005654 cites W2321102680 @default.
• W2892005654 cites W2346776290 @default.
• W2892005654 cites W2510576968 @default.
• W2892005654 doi "https://doi.org/10.1007/5584_2018_262" @default.
• W2892005654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30191431" @default.
• W2892005654 hasPublicationYear "2018" @default.
• W2892005654 type Work @default.
• W2892005654 sameAs 2892005654 @default.
• W2892005654 citedByCount "11" @default.
• W2892005654 countsByYear W28920056542018 @default.
• W2892005654 countsByYear W28920056542019 @default.
• W2892005654 countsByYear W28920056542020 @default.
• W2892005654 countsByYear W28920056542021 @default.
• W2892005654 countsByYear W28920056542022 @default.
• W2892005654 countsByYear W28920056542023 @default.
• W2892005654 crossrefType "book-chapter" @default.
• W2892005654 hasAuthorship W2892005654A5031472089 @default.
• W2892005654 hasAuthorship W2892005654A5031555208 @default.
• W2892005654 hasAuthorship W2892005654A5059191670 @default.
• W2892005654 hasAuthorship W2892005654A5069360360 @default.
• W2892005654 hasAuthorship W2892005654A5075756419 @default.
• W2892005654 hasConcept C126322002 @default.
• W2892005654 hasConcept C141071460 @default.
• W2892005654 hasConcept C187212893 @default.
• W2892005654 hasConcept C197934379 @default.
• W2892005654 hasConcept C203014093 @default.
• W2892005654 hasConcept C2777035104 @default.
• W2892005654 hasConcept C2777425658 @default.
• W2892005654 hasConcept C2778048844 @default.
• W2892005654 hasConcept C2778269047 @default.
• W2892005654 hasConcept C2778397455 @default.
• W2892005654 hasConcept C2781059491 @default.
• W2892005654 hasConcept C2781382166 @default.
• W2892005654 hasConcept C501593827 @default.
• W2892005654 hasConcept C71924100 @default.
• W2892005654 hasConcept C86803240 @default.
• W2892005654 hasConcept C89423630 @default.
• W2892005654 hasConceptScore W2892005654C126322002 @default.
• W2892005654 hasConceptScore W2892005654C141071460 @default.
• W2892005654 hasConceptScore W2892005654C187212893 @default.
• W2892005654 hasConceptScore W2892005654C197934379 @default.
• W2892005654 hasConceptScore W2892005654C203014093 @default.
• W2892005654 hasConceptScore W2892005654C2777035104 @default.
• W2892005654 hasConceptScore W2892005654C2777425658 @default.
• W2892005654 hasConceptScore W2892005654C2778048844 @default.
• W2892005654 hasConceptScore W2892005654C2778269047 @default.
• W2892005654 hasConceptScore W2892005654C2778397455 @default.
• W2892005654 hasConceptScore W2892005654C2781059491 @default.
• W2892005654 hasConceptScore W2892005654C2781382166 @default.
• W2892005654 hasConceptScore W2892005654C501593827 @default.
• W2892005654 hasConceptScore W2892005654C71924100 @default.
• W2892005654 hasConceptScore W2892005654C86803240 @default.
• W2892005654 hasConceptScore W2892005654C89423630 @default.
• W2892005654 hasLocation W28920056541 @default.
• W2892005654 hasLocation W28920056542 @default.
• W2892005654 hasOpenAccess W2892005654 @default.
• W2892005654 hasPrimaryLocation W28920056541 @default.
• W2892005654 hasRelatedWork W1480418187 @default.
• W2892005654 hasRelatedWork W1966428816 @default.
• W2892005654 hasRelatedWork W1976954360 @default.
• W2892005654 hasRelatedWork W2022310297 @default.
• W2892005654 hasRelatedWork W2038222406 @default.
• W2892005654 hasRelatedWork W2051745299 @default.
• W2892005654 hasRelatedWork W2123067954 @default.
• W2892005654 hasRelatedWork W2136820849 @default.
• W2892005654 hasRelatedWork W2892005654 @default.
• W2892005654 hasRelatedWork W4246525204 @default.
• W2892005654 isParatext "false" @default.
• W2892005654 isRetracted "false" @default.

• next